Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 5Cholangiocarcinoma 4Stomach Neoplasms 3Neoplasms 3Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Biliary Tract Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Advanced and Metastatic Urothelial Cancer 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × futibatinib × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Taiho Oncology, Inc.

Phase 1 Terminated
38 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡